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Abstract
Background
Congenital toxoplasmosis is a serious but preventable and treatable disease. Gestational screening facilitates
early detection and treatment of primary acquisition. Thus, fetal infection can be promptly diagnosed and
treated and outcomes can be improved.
Methods
We tested 180 sera with the Toxoplasma ICT IgG-IgM point-of-care (POC) test. Sera were from 116
chronically infected persons (48 serotype II; 14 serotype I-III; 25 serotype I-IIIa; 28 serotype Atypical,
haplogroup 12; 1 not typed). These represent strains of parasites infecting mothers of congenitally infected
children in the U.S. 51 seronegative samples and 13 samples from recently infected persons known to be IgG/
IgM positive within the prior 2.7 months also were tested. Interpretation was confirmed by two blinded
observers. A comparison of costs for POC vs. commercial laboratory testing methods was performed.
Results
We found that this new Toxoplasma ICT IgG-IgM POC test was highly sensitive (100%) and specific (100%)
for distinguishing IgG/IgM-positive from negative sera. Use of such reliable POC tests can be cost-saving and
benefit patients.
Conclusions
Our work demonstrates that the Toxoplasma ICT IgG-IgM test can function reliably as a point-of-care test to
diagnose Toxoplasma gondii infection in the U.S. This provides an opportunity to improve maternal-fetal care
by using approaches, diagnostic tools, and medicines already available. This infection has serious, lifelong
consequences for infected persons and their families. From the present study, it appears a simple, low-cost
POC test is now available to help prevent morbidity/disability, decrease cost, and make gestational screening
feasible. It also offers new options for improved prenatal care in low- and middle-income countries.
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Abstract
Background
Congenital toxoplasmosis is a serious but preventable and treatable disease. Gestational
screening facilitates early detection and treatment of primary acquisition. Thus, fetal infec-
tion can be promptly diagnosed and treated and outcomes can be improved.
Methods
We tested 180 sera with the Toxoplasma ICT IgG-IgM point-of-care (POC) test. Sera were
from 116 chronically infected persons (48 serotype II; 14 serotype I-III; 25 serotype I-IIIa; 28
serotype Atypical, haplogroup 12; 1 not typed). These represent strains of parasites infect-
ing mothers of congenitally infected children in the U.S. 51 seronegative samples and 13
samples from recently infected persons known to be IgG/IgM positive within the prior 2.7
months also were tested. Interpretation was confirmed by two blinded observers. A compari-
son of costs for POC vs. commercial laboratory testing methods was performed.
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Results
We found that this new Toxoplasma ICT IgG-IgM POC test was highly sensitive (100%) and
specific (100%) for distinguishing IgG/IgM-positive from negative sera. Use of such reliable
POC tests can be cost-saving and benefit patients.
Conclusions
Our work demonstrates that the Toxoplasma ICT IgG-IgM test can function reliably as a
point-of-care test to diagnose Toxoplasma gondii infection in the U.S. This provides an
opportunity to improve maternal-fetal care by using approaches, diagnostic tools, and medi-
cines already available. This infection has serious, lifelong consequences for infected per-
sons and their families. From the present study, it appears a simple, low-cost POC test is
now available to help prevent morbidity/disability, decrease cost, and make gestational
screening feasible. It also offers new options for improved prenatal care in low- and middle-
income countries.
Author summary
Toxoplasmosis, a disease caused by the parasite Toxoplasma gondii, presents a major
health burden in both the developed and developing world. Untreated congenital toxo-
plasmosis causes damage to the eye and brain, but early detection and treatment reduce
transmission and disease. Fetal infection can be promptly diagnosed and treated and out-
comes can be improved. Gestational screening for toxoplasmosis has international prece-
dent. In this paper, we demonstrated that the new Toxoplasma ICT IgG-IgM test had
100% sensitivity and specificity in detecting Toxoplasma infection (N = 180 U.S. sera from
uninfected persons and those with varying parasite serotypes). The use of an inexpensive,
easy-to-use point-of-care test facilitates screening of pregnant women for T. gondii infec-
tion. In turn, this facilitates prompt treatment for the infection and thereby reduces the
health burden caused by this disease. This provides an opportunity to improve maternal-
fetal care by using approaches, diagnostic tools, and medicines already available.
Introduction
Toxoplasmosis, a disease caused by the Apicomplexan parasite Toxoplasma gondii, remains a
major source of morbidity and mortality in the United States and globally. It causes a wide
range of clinical manifestations, varying from a self-limited minor illness to devastating eye
disease, congenital infection, and meningoencephalitis [1–4]. Treatment is currently imper-
fect, with available medicines effective against the active tachyzoite stage but not the slower-
growing bradyzoite stage. In 2012, an estimate of annual morbidity from congenital toxoplas-
mosis was made [5]. If this estimate is applied to a 10-year time period, there would be 1.9 mil-
lion new cases of congenital toxoplasmosis globally, causing 12 million disability-adjusted life
years (DALYs) [5].
There is renewed interest in this organism in light of the more widespread recognition that
2–3 billion people are infected with this parasite with the potential to reactivate and cause life-
threatening disease when significant immunosuppression occurs in these individuals. In addi-
tion, there is increasing evidence about its role in chronic inflammatory changes, epilepsy, and
Point-of-care testing for Toxoplasma gondii
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possibly neurodegenerative and neurobehavioral disease in some cases. Recent, new com-
pounds with documented efficacy against the latent, encysted bradyzoite life-stage, as well as
effective vaccines for prevention of disease in mice, have potential to reach human trials in the
not-so-distant future [6–10]. However, current patients continue to suffer profound effects
from this parasitic infection. It has been well-documented that early treatment of infected
mothers decreases risk of transmission to the fetus and severity of clinical disease and therefore
improves clinical outcomes [11]. In several countries, including France, Austria, and Uruguay,
mandatory screening for this infection during gestation has saved lives and reduced morbidity
and mortality [11–14]. However, while serologic screening has been demonstrated to be cost
saving in countries that constrain costs of testing and medications, there is no screening pro-
gram in the United States [15, 16]. Definition of better strategies to prevent this neglected,
rarely diagnosed, and thus often untreated or mistreated disease is needed.
As a result, we reasoned that development and validation of accurate, easy-to-use, and inex-
pensive point-of-care (POC) testing could help solve this problem. A novel POC test, the Toxo-
plasma ICT IgG-IgM (LDBIO Diagnostic, Lyon, France; LDBIO) presents a unique
opportunity, as it has been found to be accurate for detection of infection in France [17], and it
is both economical, at ~US$4–8 per test, and rapid, with results available within 20 minutes,
and requires no machinery. The cost we were charged was $4 and the list price was $8. $4 is
used in our considerations from here on. It has been found to be reliable with low antibody
titer sera and reliable when testing sera during seroconversion of pregnant women. For exam-
ple, it was sensitive and specific for sera from a pregnant woman who initially was seronega-
tive, then had only IgM, and lastly had IgG and IgM specific for T. gondii. The test is being
used in France and has been studied with a French cohort in Lyon, where it was found to be
both sensitive and specific. However, as has been documented previously, the population of
European T. gondii is more genetically uniform, with predominance of Type II strains, which
is distinct from the parasites found in the Western Hemisphere. Congenital Toxoplasma infec-
tion in the United States is caused by a more eclectic group of parasites, with Type II, Type
I-III, and Atypical parasites (non-II) causing disease. Given the genetic diversity that charac-
terizes the U.S. population of T. gondii, we felt it was important to assess ease of performance,
sensitivity, specificity, and positive and negative predictive value of the test for U.S. patients.
The National Collaborative Chicago-Based Congenital Toxoplasmosis Study (NCCCTS)
cohort is well characterized, with sera stored from these patients evaluated across many
decades. We tested these samples for parasite serotype [18]. Herein, we present the application
of this novel POC testing to distinctly American sera with the goal of preliminary validation of
its use for patients in the United States.
Methods
Obtaining serologic samples
Serologic samples were obtained from those in the NCCCTS cohort, as well as from volun-
teers. All seropositive persons had serum tested using gold-standard serologic testing in the
Palo Alto Reference Laboratory previously with Sabin-Feldman Dye Test and IgM ELISA,
with the exception of some seronegative volunteers, who were tested in the University of Chi-
cago Hospitals CLIA-approved Clinical Laboratory, which currently uses a Bio-Rad assay [18,
19]. Mothers of congenitally infected children in the NCCCTS also had their sera tested with a
peptide ELISA to determine II, NE-II (I/III) or I-IIIa, or Atypical (response to II = NE/II) sero-
type, as described earlier [18]. Among our samples, there were 13 sera obtained from mothers
within 2.7 months of birth of their congenitally infected child. Seronegative persons were
Point-of-care testing for Toxoplasma gondii
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laboratory personnel and fathers or adoptive mothers of congenitally infected children (18
women, 33 men).
POC testing specifics
The POC testing materials were purchased from LDBIO in Lyon, France (http://www.
ldbiodiagnostics.com). Additional details concerning this test are described in Chapey, Wal-
lon, and Peyron [17].
Serologic sample testing protocol
Sera had been stored at −20 or −80˚C prior to testing and were thawed completely. Using a
micropipette, 30 μL of serum was removed and placed into the well of the POC test. Three
drops of eluent (provided in a dispensing bottle for drops in the kit) were then placed in the
well. All POC tests were interpreted after 20 minutes. Results were interpreted by two individ-
uals blinded to whether the serum was known to be positive or negative or of a certain parasite
serotype. They determined whether the test was positive (as indicated by a pink, positive line
and a blue, positive control line on the test) or negative (as indicated by the absence of the
aforementioned pink, positive line and the presence of the blue, positive control line). This
confirmed interpretation.
Comparison of POC results with conventional serologic testing
Once the samples had been interpreted to be positive or negative, the data were compared to
records of serologic testing maintained for the NCCCTS cohort for the purposes of statistical
analysis. Earlier serological testing had been performed and interpreted by the Palo Alto Medi-
cal Foundation Toxoplasma Serology Laboratory (PAMF-TSL) [20]. A standard formula for
sensitivity, specificity, positive predictive value, and negative predictive value was used to
determine test characteristics for these samples [21, 22].
Cost comparisons
We calculated the cost of monthly prenatal screening throughout gestation for toxoplasmosis
in the U.S. using the Toxoplasma ICT IgG-IgM test as a POC test in the OB/GYN healthcare
provider office (that costs $4-8/test) versus a commercially available Toxoplasma IgG and IgM
test (that costs $650 for the Toxoplasma IgG and IgM).
Ethics
The NCCCTS was/is conducted with ethical standards for human experimentation established
in the Declaration of Helsinki, with prior University of Chicago Institutional Review Board
approval (University of Chicago IRB Protocols 8793, 8796, 8797, 15408A, and 16708A) and in
accordance with Health Insurance Portability and Accountability Act regulations. It was
reviewed regularly by a Data Safety Monitoring Board. Informed consents were obtained from
subjects for all aspects of the NCCCTS, including collection of serum samples, in accordance
with University of Chicago Institutional Review Board and National Institutes of Health guide-
lines. All adult subjects provided informed consent. For any participant under the age of 18
years old, a parent or guardian provided informed consent on behalf of the subject. All consent
was written, except for some volunteers who were not part of the NCCCTS, who provided oral
consent. These volunteers who provided oral consent did so decades ago, at a time when
obtaining written consent was not a usual part of obtaining a serum sample. Oral consent was
witnessed. All serum samples were obtained with IRB approval.
Point-of-care testing for Toxoplasma gondii
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Statistics
ANOVA was used to assess differences within groups with respect to time from the birth of an
infected baby to the collection of serum samples. Given the tendency for duration data to be
skewed, the results of ANOVA were confirmed with Kruskal-Wallis. P < 0.05 was considered
to be significant for time from birth to sample obtained.
Results
Samples tested
Results are from the following 116 serum samples from chronically infected persons tested: 48
samples from patients infected with Type II parasites, 14 samples from patients infected with
Type I-III parasites, 25 samples from patients infected with Type I-IIIa parasites, 28 samples
from patients infected with Atypical-type parasites, and 1 sample from a patient who was not
typed. Thirteen additional samples were from acutely infected persons (less than 2.7 months
since birth of their congenitally infected child). These 13 acutely infected persons with serum
tested at the time of their primary infection included: 5 samples from patients infected with
Type II parasites, 1 sample from a patient infected with Type I-III parasites, 4 samples from
patients infected with Atypical-type parasites, and 3 samples from patients infected with para-
sites of unknown serotype. 51 samples from seronegative persons also were tested.
Comparison of Toxoplasma ICT IgG-IgM POC test versus reference
Toxoplasma serologic testing
Fig 1 and S1 Table show the time from the birth of a T. gondii-congenitally infected child to
when the sample was obtained, organized by parasite serotype. S1 Table has the serologic test
results for the mother at the time of diagnosis of her child that documents her seropositivity.
This includes children diagnosed at birth. There were no false positives or false negatives. Test
characteristics, including sensitivity, specificity, positive likelihood ratio, and negative likeli-
hood ratio, are in Tables 1–3. The Toxoplasma ICT IgG-IgM test proved highly sensitive
(100%) and specific (100%) in testing human sera from patients with infections with T. gondii
strains circulating in the United States. There was no significant difference between samples
based on serotype with respect to the time from the birth of an infected baby to sample collec-
tion by ANOVA (p = 0.59) and Kruskal-Wallis (p = 0.52).
Cost
Table 4 summarizes cost calculations for prenatal screening in the U.S. using the Toxoplasma
ICT IgG-IgM POC test. In this table, we also contrast cost for standard anti-T. gondii IgM and
IgG testing in a commercial laboratory at a university hospital. In Table 4, we considered what
a person with indemnity insurance that paid in full in one U.S. hospital is charged. This infor-
mation was provided by the hospital laboratory (Table 4). This is contrasted with reagent costs
and the time for a medical assistant or technician to perform the Toxoplasma ICT IgG-IgM
test. This analysis was with serum, or cost for whole blood collected from finger prick. This
includes costs for materials, reagents, time for performing and interpreting the test and enter-
ing the result into the patient’s medical record (Table 4). We have previously shown that for
the United States, at a cost of $12 per test and prevalence as low as 1/10,000 live births, monthly
prenatal screening with treatment was found to be cost-saving [15]. This was without address-
ing costs of quality of life or suffering for families and patients, the prevention of which confers
separate and profound benefit for a program with testing, accurate diagnosis, and treatment. A
$4 point-of-care test ($4 was the charge we paid; $8 is listed on the website) increases the cost-
Point-of-care testing for Toxoplasma gondii
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savings over what was demonstrated in detailed cost-benefit studies for the United States and
Austria [12]. In terms of charges actually billed, if the cost were $650 for testing once, as it is at
present in a university hospital, then ten tests (that would be needed for monthly testing dur-
ing pregnancy) would cost $6,500 for one pregnancy. This far exceeds the capacity of an obste-
trician to function within his or her $1,000 capitation for providing care per pregnancy.
However, at $40 per pregnancy for ten tests (that would be needed for monthly testing during
Fig 1. Chronically/Subacutely infected patients by parasite serotype as a function of time from birth of congenitally infected baby to sample
obtained and seronegative patients. Toxoplasma ICT IgG-IgM test results and parasite serotype. Results were obtained using sera from chronically,
subacutely, and acutely infected persons with differing parasite serotype as a function of time from birth of this congenitally infected infant to when the
sample was obtained. These are results from sera that have been stored at varying times after visits of families to the NCCCTS. Acute sera were
collected2.7 months after the birth of the congenitally infected person and are shown with red symbols. Chronic subacute sera, shown with black
symbols, were from 145 to 9500 days after the birth of the congenitally infected person. Almost all persons had been serotyped earlier in the study.
There was one father tested and one congenitally infected adult. The serum samples, otherwise, were from mothers at the times from birth of the
infected person. S1 Table presents these detailed data. This S1 Table also presents the mother’s serologic test results at the time of the congenitally
infected person’s birth or in the case of congenitally infected persons missed at birth and presenting later in life (historical cohort) at the time of the first
visit to Chicago. These data demonstrate functioning of the Toxoplasma ICT IgG-IgM with sera from parasites that have caused congenital
toxoplasmosis in the U.S. They are not from pregnant women. This was already tested in France where this test has performed well. Duration from
birth provides relatively precise time for the chronic infection in persons who have been carefully followed longitudinally, prospectively. The data
presented had no statistically significant difference (P > 0.05) between time from the birth of a congenitally infected baby and obtaining the serum
sample related to serotype, as determined by ANOVA (P = 0.59) and secondarily confirmed by Kruskal-Wallis (P = 0.52). This timing indicates that the
Toxoplasma ICT IgG-IgM POC test is reliable in identifying acutely infected U.S. persons and subacutely and chronically infected U.S. persons even
many years after infection. The 13 acute sera,2.7 months from time of birth, were also positive. Mean and standard deviation are indicated. a In S1
Table, samples from chronically/subacutely infected persons (>2.7 months after birth of an infected baby); b Total includes samples from persons who
are either acutely (2.7 months after birth of an infected infant) and chronically/subacutely infected.
https://doi.org/10.1371/journal.pntd.0005670.g001
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pregnancy), this becomes a feasible opportunity to prevent, diagnose, and treat accordingly
this infection and its consequences.
Discussion
Herein, this novel Toxoplasma ICT IgG-IgM POC test for Toxoplasma IgG and IgM has
proven very effective at identifying that sera of U.S. patients with known T. gondii infection are
seropositive, and distinguishes them from those without serologic evidence of infection. It is
also capable of identifying sera of acutely infected patients with high accuracy [17]. This new
test has proven to be an effective screening method; it is accurate, rapid, and inexpensive. We
were charged US$4 per test kit.
The novel POC test, the Toxoplasma ICT IgG-IgM test (LDBIO Diagnostic, Lyon, France;
LDBIO), is already commercially available in France and represents a unique opportunity, as it
has already been found to have a very good diagnostic performance when tested for detection
of Toxoplasma infections from T. gondii strains circulating in France [17]. Moreover, it is both
economical, at US$4–8 per test, and rapid, with results available within 20 minutes, and
requires no large equipment. In the prior validation study in France, the Toxoplasma ICT
IgG-IgM test was tested with 400 samples (99 positive for IgG and/or IgM and 301 negative for
IgG/IgM when tested with the reference, widely commercially used, Architect automated
chemiluminescence test). There were zero false negative Toxoplasma ICT IgG-IgM test results,
while 13 false-positive Toxoplasma ICT IgG-IgM test results were identified among 301 sero-
negative samples. The Toxoplasma ICT IgG-IgM test correctly identified 21 positive sample
that had only low IgG titers and also was reliable when testing sera during seroconversion of 5
pregnant women. Specifically, the Toxoplasma ICT IgG-IgM correctly characterized a preg-
nant woman who initially was seronegative by the Architect test (Architect negative; Toxo-
plasma ICT IgG-IgM negative), then had only IgM (Architect IgM positive, IgG negative;
Table 1. Summary of results with Toxoplasma ICT IgG-IgM test and reference tests: Summary of data used to calculate sensitivity and specificity.
Reference Testing
Reference Positivea Reference Negativeb Total
Toxoplasma ICT IgG-IgM Result Positive 129 0 129
Negative 0 51 51
Total 129 51 180
a Based on gold-standard serologic testing at PAMF-TSL at earlier time when child diagnosed
b Based on testing at PAMF-TSL or the University of Chicago Laboratory (Methods used included Vidas IgG, Bio-Rad IgG, bioMerieux Direct Agglutination,
at various times)
https://doi.org/10.1371/journal.pntd.0005670.t001
Table 2. Summary of results with Toxoplasma ICT IgG-IgM test and reference tests: Subgroup breakdown.
Subgroups Chronic/Subacute a Acute b Negative c Total
Toxoplasma ICT IgG-IgM Positive 116 13 0 129
Toxoplasma ICT IgG-IgM Negative 0 0 51 51
Total 116 13 51 180
a > 2.7 months after the birth of an infected baby
b 2.7 months after the birth of an infected baby
c Based on testing at PAMF-TSL or the University of Chicago Laboratory (Methods used included Vidas IgG, Bio-Rad IgG, bioMerieux Direct Agglutination,
at various times)
https://doi.org/10.1371/journal.pntd.0005670.t002
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Table 4. Economic considerations for point-of-care test compared to hospital-administered test.
Test Type Cost per
Test (USD)
Cost per Pregnancy (10
Tests) (USD)
Cost for 100 Pregnancies (Estimate of
an Obstetrical Practice) (USD)
Cost Savings on
Testing Alone (USD)
Standard testing for T. gondii (at the
University of Chicago Hospitals)
$650 $6,500a $650,000 $0
Standard testing for T. gondii (estimate
per Stillwaggon et al. [15])
$12 $120 $12,000 $638,000
Toxoplasma ICT IgG-IgM POC test with
“bookend” multiplexed testing
$4–8 $40–80 $4,000–8,000b $638,000–646,000c
Toxoplasma ICT IgG-IgM POC test with
fingerprick on whole blood
$4.95d $49.50 $4950 $645,050
Toxoplasma ICT IgG-IgM POC test with
saliva
$5.55e $55.50 $5550 $644,450
a Well above standard capitation for pregnancy.
b Initial investment for POC testing will also include BD Microtainer Tubes: US$38.25 for 50 tubes, Sprout Centrifuge: US$228, Class I biosafety cabinet: US
$6,546; this cost is still lower than conventional testing and substantial cost savings remains.
c Cost-savings could be many fold greater by multiplexing testing for HIV, syphilis, CMV, hepatitis B, herpes simplex, and potentially Zika virus or
Trypanosoma cruzi, along with T. gondii IgG and IgM. This could reduce costs associated with individual testing. Additionally, monthly testing could
enhance maternal-child healthcare by increasing interactions with physicians, promoting screening for pre-eclampsia and gestational diabetes.
d This cost includes the cost of the Toxoplasma ICT IgG-IgM test as well as the cost of an individual lancet (estimated at US$0.33) and a Sarstedt Minivette
POCT collection pipette (estimated at US$0.62); collection of whole blood obviates need for initial investment for centrifuge, electricity.
An extra 1 ml tube of serum obtained at the time of other tests and brought by the patient to a nurse’s aide or technician, in an outpatient setting who
centrifuges the sample to collect serum, or collection of finger prick blood, takes 4–5 minutes of working time. Time as cost to place serum or obtain whole
blood and buffer onto the Toxoplasma ICT IgG-IgM test strip and interpret results after 20 minutes (~5 seconds for each task after obtaining the blood) is
included in those 4–5 minutes. Another 2 minutes is needed to enter the result in an electronic database like EPIC or less time if it is a hand written chart.
This is the same procedure that is used in the obstetrics practice in the same hospital where the charge for the standard list costs for a patient with indemnity
insurance was obtained. Total medical assistant or technician time per patient is ~6 minutes. Hourly wage (including benefits) for the technician in the same
hospital is ~$20. Thus, ~6 minutes of his/her time is ~$2. Costs for tube, devices used for finger stick, alcohol wipe, gauze, Band-Aid would add another ~
$0.25. Costs for time discussing results with the patient are the same in all scenarios as are costs for confirmatory testing when initial testing shows infection
was acquired recently during gestation. Multiplexed nano testing reduces costs further, with first test at 11 weeks gestation and then at term. This reduces
ambiguity about IgG and IgM seropositivity, facilitating avidity and other reference laboratory testing when needed.
e This cost includes the Toxoplasma ICT IgG-IgM test and the cost of a saliva swab (Beaver-Visitec- #58109, US$0.79 each) and a swab storage tube
(Salimetrics- US$0.76 each)
https://doi.org/10.1371/journal.pntd.0005670.t004
Table 3. Summary of results with Toxoplasma ICT IgG-IgM test and reference tests: Test parameters
of Toxoplasma ICT IgG-IgM POC test.
Test Parameter Result 95% CI
Sensitivitya 100% 97.18–100%
Specificityb 100% 93.02–100.00%
Positive likelihood ratioc N/A (specificity 100%) N/A (specificity 100%)
Negative likelihood ratiod 0.00 0.00
a Sensitivity = TP/(TP + FN), where TP = number of true positives, FN = number of false negatives
b Specificity = TN/(TN + FP), where TN = number of true negatives, FP = number of false positives
c Positive likelihood ratio = (sensitivity)/(1 − specificity)
d Negative likelihood ratio = (1 − sensitivity)/(specificity)
https://doi.org/10.1371/journal.pntd.0005670.t003
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Toxoplasma ICT IgG-IgM positive), and lastly had IgG and IgM specific for T. gondii (Archi-
tect IgG and IgM positive; Toxoplasma ICT IgG-IgM positive) [13]. We did not encounter in
testing the U.S. sera the few false-positive results found in France in the prior validation of the
Toxoplasma ICT IgG-IgM test in France. A total of 580 sera were tested using the Toxoplasma
ICT IgG-IgM POC test, i.e., in the present Toxoplasma ICT IgG-IgM validation study in the U.
S. (180 sera), and in the prior Toxoplasma ICT IgG-IgM validation study in Lyon, France, by
Chapey et al. (400 sera) [17]. This included in total 228 positive samples and 353 negative sam-
ples by reference T. gondii serologic testing.
In the U.S., there was 100% sensitivity and specificity, with perfect correlation with sero-
logic status. In France, performance was also excellent, with 97% sensitivity and 96% specificity
and documentation that seroconversion was detected in pregnant women in this commercially
available test, already approved for clinical use in France. In France, there were 13 false positive
sera among 109 true negative sera. There were 3 false positive nonspecific IgMs in true nega-
tive sera in France for these three reference Architect test results. In subsequent testing, these 3
women did not develop T. gondii-specific IgG. Thus, this test appears to be comparable to
other standard, commercially available, conventional serologic tests, and it appears to detect
infection with parasites found in France and in the U.S. Practically, for this combined IgG/
IgM testing, a positive result would precipitate confirmatory testing [23]. Therefore, if any
false-positive results did occur, they would be detected with the follow-up testing and not
result in harm to the patient. As this test is used, it is a screening test, and patients should be
informed that confirmatory testing will be necessary for a positive result.
Testing with such a POC test like Toxoplasma ICT IgG-IgM test could bring with it, espe-
cially in low- and middle-income settings, the incentive for ideal, more frequent monthly
obstetrical care for pregnant women, improving maternal and child health. Additional cost
savings and maternal-fetal health benefit could occur with multiplexed testing at the beginning
and end of gestation. This could screen the patient not only for Toxoplasma infection, as with
the Toxoplasma ICT IgG-IgM POC testing, but also for HIV, syphilis, hepatitis B, CMV IgG
and IgM, herpes zoster, and immunity to rubella [24, 25]. Inclusion of other pathogens, such
as Zika virus or Trypanosoma cruzi, the causative agent of Chagas disease, could also be benefi-
cial in areas where those infections are prevalent. This multiplexed testing at the beginning
and end of gestation, in combination with Toxoplasma ICT IgG-IgM POC testing on a
monthly basis between the two multiplexed tests, could be remarkably cost-saving for patients
and healthcare systems more broadly. It could facilitate profound improvement in quality of
life and care for whole families. The considerations outlined in Fig 2 demonstrate many poten-
tial benefits from an inexpensive POC-based prenatal screening program and the “spillover”
improvements in health care and outcomes that can result.
Of note, the test was not effective in the analysis of saliva and we were advised by the manu-
facturer that, in its present iteration, it was not reliable for testing whole blood when patients
had low levels of antibodies, as the pink indicator was obscured by a yellow color from the
whole blood (D. Limone, personal communication to R. McLeod, 2016). Preliminary tests
showed it could detect antibodies in a few persons. However, further work to create a test with
a dark-colored indicator is underway with future studies planned similar to those described
initially by Chapey et al. for the Toxoplasma ICT IgG-IgM test when first tested in France (FP,
PL) [17]. POC tests function well for other infections such as HIV. POC testing for T. gondii
based on testing saliva would reduce the need for venipuncture or fingerstick.
The data herein with sera from U.S. patients infected with Type II, I/III, I/IIIa, and Atypical
parasites demonstrate that the pink line indicator works well. The black indicator kit utilizes
the same antigen and test strip so detection of infections with U.S. parasites would be compa-
rable. We also wanted to develop a method whereby this test, proven herein to be very high-
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Fig 2. Gestational screening to save mothers’ and children’s lives and health care costs. Screening
pregnant women for acquisition of T. gondii infection during gestation using inexpensive point-of-care tests
will help in countries with limited resources as well as in countries that have abundant resources but do not
have gestational screening programs, such as the U.S. a Photograph reproduced with permission.
https://doi.org/10.1371/journal.pntd.0005670.g002
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functioning, could be made a true point-of-care test with serum in a setting without use of a
central laboratory. Thus, we developed a simple, practical method whereby this could be safely
utilized in an obstetrical outpatient setting. Although more complicated than testing whole
blood from a fingerprick, this approach makes the test feasible at very low cost following a
small initial investment. This approach of obtaining serum in the clinic and testing is likely to
be replaced in some settings with a test for whole blood currently in development, should it
prove to be as sensitive and specific. Whole blood obtained by fingerstick, or saliva, is useful
when processing of sera in a central laboratory is costly or inconvenient. Further, more exten-
sive testing is needed for confirmation that this test with the dark colored indicator can be
used with whole blood. This would not require electricity, centrifuges, or anything beyond a
capillary tube, lancet, and the test kits at point of care.
Despite these present limitations, this test has the potential for true clinical utility in identi-
fying those who need further serologic testing and separating them from those for whom no
further screening during pregnancy would be required. In a hypothetical clinical scenario, all
pregnant women could be screened at the outset of their visits with an obstetrician or midwife,
perhaps even using a multiplexed test for multiple congenital pathogens and T. gondii IgG and
IgM separately [24]. Should the patient’s serum screen positive for Toxoplasma IgG/IgM, she
could subsequently have confirmatory serologic testing at a reference laboratory for Toxo-
plasma infection performed. Ideally, this would begin at 11 weeks gestation or earlier. If the
patient were truly acutely infected in this gestation, based on the results of confirmatory testing
at a reference laboratory, she could receive appropriate therapy to reduce the risk of transmis-
sion to her fetus as well as the severity of potential clinical disease in the fetus [12, 13]. Should
she be identified as chronically infected, she would no longer need further screening for the
rest of her gestation. On the other hand, should a patient be negative for both IgG and IgM
with the POC test, she could undergo testing on an ongoing, monthly basis during her visits
with her obstetric care provider and one month post-partum (to allow also for detection of
infections acquired very late in gestation, which nevertheless could have clinical implication
for the management of the newborn infant). This will allow rapid detection of seroconversion,
as shown with samples obtained in France during seroconversion [17]. Results of the Toxo-
plasma ICT IgG-IgM POC test will progress from negative (Fig 3, left) to positive (Fig 3, right).
This test system will facilitate early identification, diagnosis, and treatment of congenital
toxoplasmosis in a cost-saving manner. This approach has been demonstrated to reduce the
risk of vertical transmission, as well as the severity of clinical disease in the fetus, and has been
demonstrated to be robustly cost-saving in Austria [3, 11–13, 16]. This testing has the capacity
to reduce human suffering, be cost-saving for patients and health care systems, and thereby
may overcome previous objections to the implementation of screening for congenital toxoplas-
mosis during pregnancy. It is critical to test such point-of-care tests carefully, as we (FP) also
tested another licensed test system, which did not function as well. All rules and regulations
pertaining to POC testing will have to be complied with. There is an extremely promising new
technique utilizing printed strips for multiplexed tests that can cost US$0.01 (http://med.
stanford.edu/news/all-news/2017/02/scientists-develop-lab-on-a-chip-that-costs-1-cent-to-
make.html).
There are ongoing studies being performed by our research group, comparing the test stud-
ied herein with other POC tests. Some of these point-of-care tests provide separate IgG and
IgM results. If some or all of these tests work as well as the Toxoplasma ICT IgG-IgM, any, or
all, could progress to FDA or other country’s formal approvals and CLIA, or equivalent, certifi-
cation. Where serologic screening is standard, as it is now in France and Austria, there are
economies of scale and possibly other models for testing sites that lower costs. Further, with
competing tests, market forces or regulation reduce costs. One cost- benefit analyses provides
Point-of-care testing for Toxoplasma gondii
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005670 June 26, 2017 11 / 15
broadly applicable equations with sensitivity analyses based on outcomes and cost data in the
U.S. [15]. Another cost-benefit analysis provides precise, detailed, patient specific, currently
accurate data in the very recent analyses from Austria [12]. These types of analyses are complex
and beyond the scope of this present work which evaluates the performance of the Toxoplasma
ICT IgG-IgM with sera from the U.S. and considers the cost and feasibility of implementing
such testing.
In countries where obstetrical visits are less frequent than once monthly, monthly gesta-
tional testing could incentivize marked improvements in maternal gestational health care and,
when multiplexed [24], improve diagnosis of other congenital infections. The information in
Fig 2 presents an analysis of possible life and cost savings in a developing country where such
screening is implemented monthly during gestation and where urine glucose and blood pres-
sure are also tested during those visits.
Supporting information
S1 Fig. Example of testing with Toxoplasma ICT IgG-IgM test and a person whose diagno-
sis was made long after acquisition during gestation.
(TIFF)
Fig 3. Implementation of Toxoplasma ICT IgG-IgM POC testing with separation of serum at point of care and representative Toxoplasma ICT
IgG-IgM test negative and positive test results for sera. This involves a lancet to obtain the sample with fingerprick ($0.13 for the lancet and a very low
cost for alcohol wipes), a small centrifuge tube to separate the serum, a small Class II biosafety cabinet ($6546) for safe handling of samples, and a small
centrifuge for separating serum ($228), from which serum can be removed easily and be tested. The following methodology is described in Chapey [17]:
Briefly: the Toxoplasma ICT IgG-IgM assay is based on a lateral flow chromatographic immunoassay (LFCI) technology that allows the simultaneous
detection of T. gondii IgG or IgM antibodies in human serum/plasma [17]. A minimum sample volume of 30–50 μL of serum/plasma is required [17]. Each
cassette contains: a) a nitrocellulose strip on which there are two reactive bands, one with the Toxoplasma gondii antigen (from whole cell lysate) called
the “test” band (T band) and one with the rabbit gamma globulins called the “control” band (C band); b) a fiberglass support (conjugate pad) which is
impregnated with red latex particles coupled with Toxoplasma antigens (“test” latex = T latex) and blue latex particles coupled with goat anti-rabbit IgG
(“control” latex = C latex) [17]. The test is run by dispensing the serum/plasma and an eluting solution (eluent) in the “sample well” of the cassette [17]. With
the addition of the eluent, starts the concomitant migration (chromatography) of the serum/plasma and the latex particles [17]. If anti-Toxoplasma
antibodies (IgG or IgM or both) are present in the sample, a complex is formed between the T latex and the patient’s antibodies, which is then captured by
the T band, and it results in the appearance of a red line (positive test) [17]. The direct capture of the C latex by the C band results in the appearance of a
control blue line which indicates that the chromatography performed well [17]. The results are read 20–30 minutes after the eluent solution has been
dispensed into the well [17]. Representative example of U.S. sera, negative (left) and positive (right) results. This is the new simple POC test, based on
lateral-flow-chromatographic-immunoassay method, already commercially available in France, that detects simultaneously both Toxoplasma IgG and IgM
antibodies and costs only $4 (the cost we were charged) per test, as opposed to a $650 cost for testing at a commercial laboratory in the U.S.
https://doi.org/10.1371/journal.pntd.0005670.g003
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S1 Table. Infected patient primary data. These samples were chosen to reflect measurement
for patients in real time. The samples stored present a unique opportunity to know the precise
time from seroconversion (birth of infected infant) to the time the serum sample was obtained.
The goal was to determine whether the Toxoplasma ICT IgG-IgM POC test resulta could dis-
tinguish serum from patients infected with parasites of differing serotypes, present in the U.
S.b, from the sera of uninfected persons. We selected these serum samples at later times after
primary infection during gestation that resulted in the birth of an infected infantc. The year
reflects the time the stored sample was obtained from 1991-2016d. The serologic tests in this
table were the mother’s serologic tests at the time of the birth of an infected infante. The time
after birth the serum was obtained demonstrates that these samples were remote from the pri-
mary infection, which is what we were trying to detect. Thirteen samples closer to the time of
primary infection were also tested (labeled A). Not all samples from acutely infected persons
had serotype data available, reflected by N/A. These data are also displayed in Fig 1. An IgG
dye test is considered negative for values <1:16 and positive for values1:16 [26]. An IgM
ELISA performed with serum is considered negative for values 0.0–1.6, equivocal for values
1.7–1.9, and positive for values2.0 in serum [27]. An IgM ISAGA is positive for values3
[28]. An IgA ELISA for patients >6 months of age is considered negative for values 0.0–1.4,
equivocal for values 1.5–2.0, and positive for values2.1, and an IgA ELISA for patients <6
months of age is considered negative for values 0.0–0.9 and positive for values1.0 [29]. High
avidity signifies that infection occurred more than 4 months ago [30]. f Serology not performed
at Palo Alto Medical Foundation Toxoplasma Serology Laboratory. g Chronic seropositive
patient. h Serology values for child are listed. i Chronic seropositive father; serology values for
child are listed. H Historical control.
(DOCX)
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